Bronchiolitis obliterans (BO) is a serious complication of hematopoietic SCT (HSCT). The condition is believed to be the result of an inflammatory part of the GVHD. Although many BO patients receive immunosuppressive therapy, there is no clear evidence that therapeutic interventions have a positive impact. In the last 20 years, it has been recognized that macrolides have immunomodulatory effects beyond their antibiotic effect. Recent data suggest also that the use of macrolides in BO post HSCT may halt disease progression. Our objectives are to give the readers information on the background of BO post HSCT, to review the immunomodulatory properties of macrolides in general and specifically in pulmonary diseases, and to summarize the current knowledge of macrolide benefits in BO therapy. Research into macrolide immunomodulation for chronic pulmonary disorders, such as diffuse panbronchiolitis and cystic fibrosis, shows consistent positive effects. The use of macrolides for other types of pulmonary inflammatory complications is yet to be proved. The benefit for BO post HSCT was shown only in a small non-randomized trial. Additional in vivo research is needed before developing any firm conclusions.
Introduction
Bronchiolitis obliterans (BO) is one of the more common non-infectious pulmonary complications of allogeneic hematopoietic SCT (HSCT). [1] [2] [3] [4] Although the immunological mechanisms of this process remain poorly understood, the condition is believed to be part of the GVHD. 5, 6 Histopathological studies have shown an initial inflammatory response of terminal and respiratory bronchioli that ultimately leads to scarring and total occlusion of the conducting airways. 7, 8 Clinically it is characterized mainly by progressive irreversible airflow obstruction, which frequently leads to death due to respiratory failure. 4 Currently, there is no clear evidence that therapeutic interventions have a positive impact on the course of the disease. Many patients receive immunosuppressive therapy, but there is a lack of controlled trials to suggest any benefit. 9 Some authors found that the pathological and clinical findings are very similar to BO after lung transplantation and both share the same poor prognosis. 4 Recent data showed that the use of macrolide antibiotics may help in halting the disease progression in post-HSCT BO. 10 Macrolides appear to have, in addition to their antibiotic effect, immunomodulatory activity, which showed promising results in several inflammatory pulmonary diseases. [11] [12] [13] This review summarizes the current state of knowledge about BO as an inflammatory disease post-allogeneic HSCT, the use of macrolides for immune modulation in respiratory diseases and the major advantages of the routine use of macrolides in BO patients.
Pulmonary complications after HSCT
Allogeneic and autologous HSCT are now both established as principal forms of treatment for patients with acute or chronic leukemia, aplastic anemia and various immunodeficiency syndromes, as well as various non-hematological malignancies and autoimmune disorders.
14 However, major limitations to the successful use of HSCT include GVHD and respiratory complications. It has been found that pulmonary complications occur in up to 50% of those who undergo allogeneic HSCT and are the most common causes of morbidity and mortality after this procedure. 15 The types of pulmonary complications that occur after allogeneic HCT can be simplified by considering the time the pulmonary disease occurs and whether the radiographic abnormalities are focal or diffuse. Most early pulmonary complications are infectious; however, in the period after engraftment, the ratio of inflammatory vs infectious complications increases. Regardless of the initiating event, entities such as diffuse alveolar hemorrhage, idiopathic pulmonary syndrome, BO, cryptogenic organizing pneumonia (COP, previously named BOOP-BO organizing pneumonia), pulmonary alveolar proteinosis, pulmonary veno-occlusive disease and pulmonary fibrosis were all considered to have an underlying inflammatory mechanism. They have predictable time course and different clinical, laboratory and radiological manifestations, which may help in the differential diagnosis ( Table 1) .
The approach to the diagnosis and treatment of these patients is a major clinical challenge. An aggressive, invasive diagnostic approach with the use of bronchoscopy is usually justified. If no diagnosis is made, video-assisted thoracoscopy or even an open-lung biopsy should be strongly considered. If infection has been ruled out, suggested therapy for those inflammatory complications includes mainly high-dose glucocorticoids, which have variable clinical response. Other immunomodulatory agents such as anti-tumor necrosis factor, CY, CYA, MTX, macrolides or other anti-inflammatory drugs are still investigational. Recently, the BMT-CTN trial started recruiting HSCT patients with idiopathic pulmonary syndrome for etanercept therapy.
Bronchiolitis obliterans after HSCT
Approximately 40-60% of allogeneic recipients develop multisystem GVHD, and BO occurs in approximately 10% of GVHD patients. The development of BO is almost always associated with the presence of GVHD. 4 It is characterized by the development of fixed airway obstruction in the absence of airway infection. Typically, BO presents 6-12 months after HSCT, and it has been described that more than 90% of patients who develop symptoms of BO do so within the first 18 months after transplantation. The risk factors include chronic GVHD, human leukocyte Ag mismatch, low HSCT Ig level, immunosuppression with MTX and BU exposure, and allogeneic as opposed to autologous HSCT. 16, 17 The onset of BO is insidious and clinical symptoms are frequently misinterpreted; the disease is therefore often diagnosed at a relatively late stage. Non-productive cough and dyspnea are the major clinical manifestations. The limitations in exercise capacity are often not appreciated in a patient population, which in general is not very active physically. A close observation of these patients is therefore imperative to allow for an early diagnosis of the disease process. Chest examination is often normal, but there may be evidence of hyperinflation and diminished breath sounds. High-resolution computerized tomography of the chest, with paired inspiratory and expiratory images, is the imaging study of choice, and the characteristic findings include variable attenuation of lung parenchyma due to air trapping (mosaic attenuation) and occasional airway dilatation. Physiological testing typically shows moderateto-severe airflow limitation, with hyperinflation and gas trapping. Restrictive or mixed defects may result from a concomitant interstitial process.
Diagnosis of BO is based primarily on supportive clinical, laboratory and physiological features. Definitive diagnosis typically requires open-lung biopsy, but, given the increased risks associated with surgical procedures in this patient population, it is believed that surgical biopsy can be avoided when a consistent clinical picture is present. Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy may be performed to help exclude infectious causes. However, the sensitivity of transbronchial biopsy for diagnosing BO is limited by the patchy small airway involvement, characteristic of the disease. 16 Histopathology classically shows bronchiolar and peribronchiolar lymphocytic infiltrate with concentric fibrosis and partial-tocomplete obliteration of affected bronchioles. Thus, a characteristic clinical picture with supporting physiological, radiographic and laboratory data is paramount for obtaining a timely diagnosis on which to initiate therapy.
Treatment consists of reinstitution or augmentation of immunosuppression. Corticosteroids are the mainstay of treatment, at a dose of 1.0À1.5 mg/kg/d (a maximum dose of 100 mg/d) for 2-6 weeks, followed by tapering of dose on clinical improvement or stabilization. 17 There is currently insufficient evidence that the progressive damage of the BO can be altered by treatment. The prognosis is poor, with an overall 3-year mortality of 65%. 15 Some patients may respond to initial therapy, but substantial improvement in lung function is rare. Despite improvement in some patients with therapy, relapsing and remitting courses are common, and patients often have progressive functional impairment from irreversible airflow obstruction. Owing to the lack of effective treatment, and analogies with other bronchiolar disorders, there has been recent interest in the potential role of macrolide antibiotics in the management of HSCTassociated BO. Macrolides have shown anti-inflammatory properties in other disorders involving the bronchioles, such as asthma, cystic fibrosis and diffuse panbronchiolitis (DPB), and therefore have been suggested as a therapeutic 
Mechanisms of macrolide antibiotics as an anti-inflammatory preparation
Macrolide antibiotics have been used over the past 50 years, predominantly for their antimicrobial activity. Interest in the immunomodulatory effects of macrolide antibiotics began with the observation that patients with severe asthma required lower doses of steroids if they also had received troleandomycin. 22 Since then, macrolides have been shown to affect several pathways of the inflammatory process, such as the migration of neutrophils, the oxidative burst in phagocytes and the production of pro-inflammatory cytokines. 22, 23 Although the precise mechanisms of these effects are not clear, it has been suggested that the interaction between macrolides and leukocytes may be important. In fact, macrolide antibiotics are able to accumulate into polymorphonuclear leukocytes, reaching intracellular concentrations far higher than those attained in the extracellular fluids. [24] [25] [26] This ability may in turn alter the functions of phagocytes, which appear crucial for both the antibacterial defense and the inflammatory process often associated with infections. Some have suggested that the antioxidant properties, shared by several macrolides, may play a role in the anti-inflammatory activity of these agents. These properties of macrolides appear to be limited to the 14-membered and 15-membered macrolides, such as erythromycin, clarithromycin and azithromycin. These macrolides decrease pro-inflammatory cytokines in the serum and bronchoalveolar fluid, decrease mucus hypersecretion and may protect the airway epithelium from damage. 27 Pharmacokinetic studies 30 have suggested that the beneficial effects of troleandomycin therapy may be due, in part, to the inhibition of steroid metabolism. Troleandomycin was shown to significantly prolong the serum t 1/2 of methylprednisolone. However, in reported studies, some steroid-dependent patients were able to completely discontinue concomitant oral steroid therapy without worsening asthma severity, suggesting that troleandomycin had direct anti-inflammatory activities. Studies 31 also have shown that low-dose troleandomycin directly attenuates bronchial hyper-responsiveness in children with severe asthma and that the effects were independent of its action on glucocorticoid metabolism.
Mucus secretion-macrolide antibiotics also appear to be mucoregulatory, that is, they are able to decrease mucus hypersecretion in persons with airway disease without suppressing baseline physiological secretion. In a doubleblind, placebo-controlled, 8-week trial of 31 patients with chronic bronchitis, bronchiectasis or DPB, low-dose clarithromycin (100 mg twice daily) profoundly decreased the expectorated sputum volume from 51 to 24 g per day (Po0.001). 31 Treatment with clarithromycin also increased the percentage of solid composition and the elastic modulus of the sputum (Po0.05) but did not alter its dynamic viscosity. On the basis of these data, the investigators suggested that clarithromycin reduces both mucus and water secretion.
Clarithromycin also significantly reduced the volume of nasal mucus secretion, both at baseline and with methacholine stimulation, and improved the sneeze (airflow) transportability in 10 patients with purulent rhinitis. 19 Roxithromycin therapy for 12 weeks significantly decreased sputum volume and 'purulence' in 25 children with bronchiectasis. 20 The mechanism by which macrolides inhibit mucus hypersecretion is thought to involve decreasing the inflammatory stimulus for hypersecretion. 32 In vitro and in vivo studies also suggest that macrolides may inhibit the pulmonary influx of neutrophils, inhibit the release of pro-inflammatory cytokines, protect the epithelium from bioactive phospholipids and improve the transportability of airway secretions.
In summary, the immunomodulatory properties of 14-and 15-membered macrolides may include the following:
Decreased neutrophil chemotaxis and infiltration into the respiratory epithelium. Inhibition of transcription factors leading to decreased pro-inflammatory cytokine production. Downregulation of adhesion molecule expression. Improvement in alveolar macrophage phagocytosis of apoptotic cells. Inhibition of microbial virulence factors, including * biofilm formation; * reduced generation of oxygen-free radicals; * enhanced neutrophil apoptosis; and * decreased mucus hypersecretion with improved mucociliary clearance.
Clinical studies A number of studies 22, 28, 29 have shown an improvement in the clinical symptoms of corticosteroid-dependent patients with asthma and a reduction in corticosteroid dosage with macrolide therapy. Simpson et al. 29 showed in a randomized, placebo-controlled trial of 46 patients with refractory asthma that 8 weeks of clarithromycin improved quality of life and reduced sputum neutrophils and IL-8.
The most convincing demonstration of the immunomodulatory effects of macrolides came from Japan, in the early 1980s. It was discovered that chronic, low-dose macrolides have dramatically improved survival in patients with DPB, a chronic inflammatory pulmonary disease of unknown etiology. 18 Before this discovery, the 5-year survival rate of DPB patients was 60%, which decreased to 10% when the disease progressed to a point where patients became colonized with Pseudomonas aeruginosa. Once the utility of macrolides in the treatment of DPB became known, 5-year survival rates rose to 92% on daily erythromycin therapy. Given the overlap in pathogenesis between DPB and other chronic respiratory diseases, many investigators at the time focussed their research on the anti-inflammatory effects of macrolides.
Macrolides are being investigated also for cystic fibrosis; it is probable that patients with cystic fibrosis may realize similar benefits with long-term macrolide therapy. In nearly all reports, patients with cystic fibrosis who have received macrolide antibiotics have responded with improvements in pulmonary function.
There is also strong clinical evidence for the effectiveness of macrolides in the treatment of bronchiectasis, chronic bronchitis, chronic obstructive pulmonary disease and sinusitis, and this is the focus for ongoing research. [19] [20] [21] In conclusion, although the evidence so far accumulated shows that macrolides do exert both local and systemic anti-inflammatory effects, the mechanisms underlying these actions, and the use of macrolides independent of their antibacterial activity, are still unclear.
Macrolides for transplant-associated BO
In general, medical treatment of BO is not fully satisfactory. Once established, BO is difficult to reverse, but augmented immunosuppression using various treatment regimens may achieve stabilization or at least slow the rate of decline in FEV1 for some period of time. 1 Ultimately, progressive deterioration usually ensues.
1 Augmentation of immunosuppressive therapy often begins with corticosteroids and/or cytolytic therapy in an effort to manage an active but potentially reversible inflammatory process. The addition of azathioprine to CYA and prednisone may stabilize pulmonary function in some patients. Under these circumstances and while awaiting more effective treatment methods, minimization of risk factors for BO, especially pre-emptive treatment for CMV and early detection of BO in the asymptomatic stage likely allow the best chance for stabilization or resolution of the unfortunate disease. Owing to their association, improved measures to prevent and treat chronic GVHD will undoubtedly be of major importance in helping to prevent BO. Although the use of CYA has led to reduction in the rate of chronic GVHD, and of BO, additional immunosuppression measures will need to be balanced against an increase in the rate of opportunistic infections.
Of particular interest are recent studies of the use of azithromycin for patients with BO after transplantation procedures. A recent open-labeled study of eight human subjects after lung transplantation suggests that azithromycin, in a dosage of 250 mg/day for 5 days, followed by 250 mg every other day, when added to the patient's pre-existing immunosuppressive therapy, results in a significant improvement in the degree of airway narrowing. 33 It postulated that azithromycin may have produced this improvement by the inhibition of IL-8 release by human alveolar macrophages or by an increase in the apoptosis of neutrophils.
Another study by Khalid et al. 10 has produced further evidence to suggest that there is a potential role for azithromycin in the treatment of BO. This is an observational study of eight patients out of 153 subjects undergoing allogeneic HSCT. The eight patients with BO were given azithromycin 500 mg daily for 3 days, then 250 mg three times per week for 12 weeks. Clinically significant improvement was achieved in both forced expiratory volume in 1 second and forced vital capacity, with the average improvement being 21%. Khalid et al. 10 postulated that macrolide antibiotics may have a beneficial effect by virtue of a range of anti-inflammatory effects. This study highlights the need for continued research in this important area and provides the exciting prospect of improved patient outcome for a complication that otherwise carries a grim prognosis. It goes without saying that a major challenge exists to understand more precisely the factors, both immune and non-immune, which contribute to the development of BO after HSCT.
Summary
Although the exact pathogenesis of post-transplant BO has yet to be fully elucidated, it is probable that it is the end result of a number of repeated insults. These can include GVHD, infections or other inflammatory processes that cause airway epithelial tissue damage with a subsequent exaggerated healing response. Although it is probable that each of these injuries is additive, current evidence indicates that the alloimmune injury is the critical insult and that measures that offer the prospect of curtailing this injury offer the promise of improved survival for patients after HSCT. Currently, our ability to treat post-transplant BO is limited, and harnessing the immunomodulatory properties of macrolide antibiotics offers a promising approach. Early retrospective and small-scale studies showed that it may have a role in managing this devastating condition. In light of these studies, and in view of the poor prognosis of BO in patients after HSCT, a larger scale randomized trial to assess the benefit of this form of treatment is needed. Further studies will also determine which of the macrolides are the most effective, the duration of the effect, the longterm consequences of long-term use of these antibiotics and their mechanisms of action. This information may hopefully lead to the development of more specific therapeutic agents.
